Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Investig Drugs. 2007 Jan;8(1):71-7.

Drug evaluation: CYT-002-NicQb, a therapeutic vaccine for the treatment of nicotine addiction.

Author information

  • 1The Open University in the North, Faculty of Science, Eldon House, Regent Centre, Gosforth, Newcastle upon Tyne NE3 3PW, UK.


Cytos Biotechnology AG is developing an intramuscular therapeutic vaccine, CYT-002-NicQb (also known as nicotine-Qbeta), based on its Immunodrug (formerly known as alpha vaccine) nicotine-specific antibody-generating technology, for the potential treatment of nicotine addiction. A phase II trial was initiated in Switzerland in January 2005 and in February 2006, Cytos Biotechnology announced that it planned to begin a phase IIb/III trial in 2007.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk